Premalignant and in situ breast disease

Biology and clinical implications

Grazia Arpino, Rodolfo Laucirica, Richard M. Elledge

Research output: Contribution to journalReview article

139 Citations (Scopus)

Abstract

Most types of invasive breast cancer are thought to evolve over long periods from specific preexisting benign lesions. Of the many types of benign entities found in the human breast, only a few have clinically significant premalignant potential. Currently, the best-characterized premalignant lesions are atypical ductal hyperplasia, atypical tabular hyperplasia, and tabular carcinoma in situ. Ductal carcinoma in situ is considered to be a preinvasive malignant lesion. Two additional lesions, unfolded lobules and usual ductal hyperplasia, are sometimes considered to be very early premalignant epithelial abnormalities. Premalignant lesions are currently defined by their histologic features, and not all necessarily progress to invasive cancer. This suggests that although lesions within specific categories look alike, they must possess underlying genetic differences that cause some to remain stable and others to advance. The development of modem molecular genetic techniques has allowed breast cancer researchers to clarify the multistep model of breast carcinogenesis. Recent studies indicate that cancer evolves by highly diverse genetic mechanisms, and research into these altered pathways may identify specific early defects that might be targeted to prevent progression of premalignant lesions to invasive cancer. Current clinical management is heterogeneous and depends on histologic examination and individual patient factors. Options for breast cancer risk reduction and prevention are available.

Original languageEnglish (US)
Pages (from-to)446-457
Number of pages12
JournalAnnals of Internal Medicine
Volume143
Issue number6
DOIs
StatePublished - Sep 20 2005
Externally publishedYes

Fingerprint

Breast Diseases
Carcinoma, Intraductal, Noninfiltrating
Breast Neoplasms
Hyperplasia
Breast
Modems
Genetic Techniques
Neoplasms
Genetic Research
Carcinoma in Situ
Risk Reduction Behavior
Molecular Biology
Carcinogenesis
Research Personnel

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Premalignant and in situ breast disease : Biology and clinical implications. / Arpino, Grazia; Laucirica, Rodolfo; Elledge, Richard M.

In: Annals of Internal Medicine, Vol. 143, No. 6, 20.09.2005, p. 446-457.

Research output: Contribution to journalReview article

Arpino, Grazia ; Laucirica, Rodolfo ; Elledge, Richard M. / Premalignant and in situ breast disease : Biology and clinical implications. In: Annals of Internal Medicine. 2005 ; Vol. 143, No. 6. pp. 446-457.
@article{7738cbc0f3b74c808dfba900cb9265d6,
title = "Premalignant and in situ breast disease: Biology and clinical implications",
abstract = "Most types of invasive breast cancer are thought to evolve over long periods from specific preexisting benign lesions. Of the many types of benign entities found in the human breast, only a few have clinically significant premalignant potential. Currently, the best-characterized premalignant lesions are atypical ductal hyperplasia, atypical tabular hyperplasia, and tabular carcinoma in situ. Ductal carcinoma in situ is considered to be a preinvasive malignant lesion. Two additional lesions, unfolded lobules and usual ductal hyperplasia, are sometimes considered to be very early premalignant epithelial abnormalities. Premalignant lesions are currently defined by their histologic features, and not all necessarily progress to invasive cancer. This suggests that although lesions within specific categories look alike, they must possess underlying genetic differences that cause some to remain stable and others to advance. The development of modem molecular genetic techniques has allowed breast cancer researchers to clarify the multistep model of breast carcinogenesis. Recent studies indicate that cancer evolves by highly diverse genetic mechanisms, and research into these altered pathways may identify specific early defects that might be targeted to prevent progression of premalignant lesions to invasive cancer. Current clinical management is heterogeneous and depends on histologic examination and individual patient factors. Options for breast cancer risk reduction and prevention are available.",
author = "Grazia Arpino and Rodolfo Laucirica and Elledge, {Richard M.}",
year = "2005",
month = "9",
day = "20",
doi = "10.7326/0003-4819-143-6-200509200-00009",
language = "English (US)",
volume = "143",
pages = "446--457",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Premalignant and in situ breast disease

T2 - Biology and clinical implications

AU - Arpino, Grazia

AU - Laucirica, Rodolfo

AU - Elledge, Richard M.

PY - 2005/9/20

Y1 - 2005/9/20

N2 - Most types of invasive breast cancer are thought to evolve over long periods from specific preexisting benign lesions. Of the many types of benign entities found in the human breast, only a few have clinically significant premalignant potential. Currently, the best-characterized premalignant lesions are atypical ductal hyperplasia, atypical tabular hyperplasia, and tabular carcinoma in situ. Ductal carcinoma in situ is considered to be a preinvasive malignant lesion. Two additional lesions, unfolded lobules and usual ductal hyperplasia, are sometimes considered to be very early premalignant epithelial abnormalities. Premalignant lesions are currently defined by their histologic features, and not all necessarily progress to invasive cancer. This suggests that although lesions within specific categories look alike, they must possess underlying genetic differences that cause some to remain stable and others to advance. The development of modem molecular genetic techniques has allowed breast cancer researchers to clarify the multistep model of breast carcinogenesis. Recent studies indicate that cancer evolves by highly diverse genetic mechanisms, and research into these altered pathways may identify specific early defects that might be targeted to prevent progression of premalignant lesions to invasive cancer. Current clinical management is heterogeneous and depends on histologic examination and individual patient factors. Options for breast cancer risk reduction and prevention are available.

AB - Most types of invasive breast cancer are thought to evolve over long periods from specific preexisting benign lesions. Of the many types of benign entities found in the human breast, only a few have clinically significant premalignant potential. Currently, the best-characterized premalignant lesions are atypical ductal hyperplasia, atypical tabular hyperplasia, and tabular carcinoma in situ. Ductal carcinoma in situ is considered to be a preinvasive malignant lesion. Two additional lesions, unfolded lobules and usual ductal hyperplasia, are sometimes considered to be very early premalignant epithelial abnormalities. Premalignant lesions are currently defined by their histologic features, and not all necessarily progress to invasive cancer. This suggests that although lesions within specific categories look alike, they must possess underlying genetic differences that cause some to remain stable and others to advance. The development of modem molecular genetic techniques has allowed breast cancer researchers to clarify the multistep model of breast carcinogenesis. Recent studies indicate that cancer evolves by highly diverse genetic mechanisms, and research into these altered pathways may identify specific early defects that might be targeted to prevent progression of premalignant lesions to invasive cancer. Current clinical management is heterogeneous and depends on histologic examination and individual patient factors. Options for breast cancer risk reduction and prevention are available.

UR - http://www.scopus.com/inward/record.url?scp=24944505221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944505221&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-143-6-200509200-00009

DO - 10.7326/0003-4819-143-6-200509200-00009

M3 - Review article

VL - 143

SP - 446

EP - 457

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -